Market Overview

UPDATE: Goldman Sachs Reiterates Neutral Rating, Raises PT on Covidien plc


In a report published Monday, Goldman Sachs Group reiterated its Neutral rating on Covidien plc (NYSE: COV), and slightly raised its price target from $62.00 to $63.00.

Goldman Sachs noted, “On Monday, December 31, Covidien launched a generic version of the attention deficit hyperactivity disorder drug (ADHD) Concerta. The company will offer the product in 27, 36, and 54 milligram dose strengths, and Mallinckrodt intends to file an abbreviated new drug application for the 18mg dose in 1QCY13. The company will also have the 36mg and 54mg doses available in 1QCY13. Management indicated the company has six-month exclusivity on the doses approved today. For reference, Concerta was a $1bn+ branded product marketed by J&J, and Watson is the only other generic competitor. In conjunction with the FDA approval, Covidien raised guidance for the Pharmaceutical segment (17% of sales) from 1%-4% to 3%-6%. Total company targets are unchanged.”

Covidien plc closed on Friday at $56.31.

Latest Ratings for COV

Nov 2014MaintainsBuy
Oct 2014DowngradesOverweightEqual-Weight
Jul 2014MaintainsBuy

View More Analyst Ratings for COV
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Price Target Analyst Ratings


Related Articles (COV)

View Comments and Join the Discussion!

Latest Ratings

FNDLoop CapitalMaintains46.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Day Market Update: Political Indecision Looms, Yet Markets Rise

Miller Tabak Reiterates Hold Rating, $31.63 PT on Willis Group Holdings